Literature DB >> 9873234

Effect of Am-80, a synthetic derivative of retinoid, on experimental arthritis in mice.

H Nagai1, S Matsuura, K Bouda, Y Takaoka, T Wang, S Niwa, K Shudo.   

Abstract

Am-80 is a newly snythesized retinoid with the structure of one aromatic amide among retinobenzoic acids. It exhibits specific biological activities of retinoic acid such as the activation of cellular differentiation and proliferation. We investigated the effect of Am-80 on collagen-induced arthritis (CIA) in mice and the immunopharmacological action on the production of several cytokines in the in vitro and in vivo models. Am-80, at doses of 0.3, 1 and 3 mg/kg, significantly inhibited the severity and development of the arthritis index, progression of foot pad swelling, bone damage and histopathological alterations. Am-80 also inhibited the production of anti-type II collagen (CII) IgG antibody, but did not affect the delayed-type hypersensitivity (DTH) response in arthritic mice. To determine the inhibitory mechanism of Am-80, we studied the effect of Am-80 on the production of cytokines. Am-80 did not affect the production of IFN-gamma by Th1 cells (1E10.H2 cells) and IL-4 by Th2 cells (D10.G4.1 cells), respectively. Am-80 selectively inhibited bacterial lipopolysaccharide (LPS)-induced IL-6, but not TNF-alpha and IL-1beta, production in mice. Moreover Am-80 inhibited IL-1beta induced IL-6 production and IL-6 mRNA expression in human osteoblast-like cells (MG-63). The inhibition of IL-6 production by Am-80 was due to downregulation of the pretranscription or the transcription of IL-6 in MG 63 cells. These findings suggest that the inhibitory effect of Am-80 on CIA is partially by modulating the production of the proinflammatory cytokine, IL-6.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9873234     DOI: 10.1159/000028272

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  7 in total

Review 1.  Vitamin effects on the immune system: vitamins A and D take centre stage.

Authors:  J Rodrigo Mora; Makoto Iwata; Ulrich H von Andrian
Journal:  Nat Rev Immunol       Date:  2008-09       Impact factor: 53.106

2.  Localized Th1-, Th2-, T regulatory cell-, and inflammation-associated hepatic and pulmonary immune responses in Ascaris suum-infected swine are increased by retinoic acid.

Authors:  Harry Dawson; Gloria Solano-Aguilar; Madeline Beal; Ethiopia Beshah; Vandana Vangimalla; Eudora Jones; Sebastian Botero; Joseph F Urban
Journal:  Infect Immun       Date:  2009-03-30       Impact factor: 3.441

3.  Direct and indirect effects of retinoic acid on human Th2 cytokine and chemokine expression by human T lymphocytes.

Authors:  Harry D Dawson; Gary Collins; Robert Pyle; Michael Key; Ashani Weeraratna; Vishwa Deep-Dixit; Celeste N Nadal; Dennis D Taub
Journal:  BMC Immunol       Date:  2006-11-21       Impact factor: 3.615

Review 4.  Towards retinoid therapy for Alzheimer's disease.

Authors:  K Shudo; H Fukasawa; M Nakagomi; N Yamagata
Journal:  Curr Alzheimer Res       Date:  2009-06       Impact factor: 3.498

5.  All-trans retinoic acid suppresses interleukin-6 expression in interleukin-1-stimulated synovial fibroblasts by inhibition of ERK1/2 pathway independently of RAR activation.

Authors:  Mélanie Kirchmeyer; Meriem Koufany; Sylvie Sebillaud; Patrick Netter; Jean-Yves Jouzeau; Arnaud Bianchi
Journal:  Arthritis Res Ther       Date:  2008-12-10       Impact factor: 5.156

6.  The Retinoic Acid Receptor-alpha mediates human T-cell activation and Th2 cytokine and chemokine production.

Authors:  Harry D Dawson; Gary Collins; Robert Pyle; Michael Key; Dennis D Taub
Journal:  BMC Immunol       Date:  2008-04-16       Impact factor: 3.615

7.  The retinoic acid receptor agonist Am80 increases mucosal inflammation in an IL-6 dependent manner during Trichuris muris infection.

Authors:  Rebecca J M Hurst; Adam De Caul; Matthew C Little; Hiroyuki Kagechika; Kathryn J Else
Journal:  J Clin Immunol       Date:  2013-09-15       Impact factor: 8.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.